-
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (EVOMELA®).
-
Bringing life-changing therapeutics to China and the world.
September 10, 2019
CASI hosts a key opinion leader (KOL) symposium addressing innovations in cancer immunotherapy. A replay of Nobel Laureate James P. Allison Discussion on Immunotherapy Checkpoint Blockade in Cancer Therapy can be found at https://www.youtube.com/channel/UC5IBDAqhTqt5esL9r3dgQRQ.
August 12, 2019
EVOMELA® received market approval by the China National Medical Products Administration (NMPA) for use as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. It is the only approved and commercially available melphalan product in China.
Press Release
October 02, 2020
Press Release
September 29, 2020
Press Release
September 11, 2020
CASI Pharmaceuticals, Inc. is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China.
EVOMELA® (melphalan) for Injection, ZEVALIN® (ibritumomab tiuxetan), and MARQIBO® (vincristine sulfate LIPOSOME injection) are proprietary to Acrotech Biopharma LLC and its affiliates.
© 2020 CASI Pharmaceuticals Inc.
All Rights Reserved.
